Literature DB >> 26503013

Endovascular repair of pseudoaneurysms after open surgery for aortic coarctation.

Drosos Kotelis1, Moritz S Bischoff1, Fabian Rengier2, Arjang Ruhparwar3, Matthias Gorenflo4, Dittmar Böckler5.   

Abstract

OBJECTIVES: To analyse early and long-term results of thoracic endovascular aortic repair (TEVAR) in patients with pseudoaneurysms after open aortic coarctation (CoA) repair.
METHODS: A total of 11 patients of 418 patients who had been treated with TEVAR during the period from January 1998 to April 2015 (8 males; median age 53 years) were retrospectively analysed. Dacron patch aortoplasty was primarily performed in 9 patients and subclavian flap aortoplasty in 2 patients. Seven of the 11 patients had asymptomatic pseudoaneurysms (median diameter 56 mm, range 20-65 mm) diagnosed by routine screening. Symptomatic patients presented with haemoptysis, lower limb ischaemia, haemodynamic collapse and back pain and underwent emergency repair (4/11). Adjunctive procedures at the proximal landing zone were required in 7/11 patients. The median number of implanted endoprostheses per patient was 1 (range: 1-5). The median follow-up was 60 months (range 6-161 months).
RESULTS: Technical success was achieved in 91% (10/11; 1 secondary elective open conversion). The 30-day mortality was 0%. The stroke rate was 18% (2 non-disabling strokes). In 2 patients (20%), stent-graft displacement during deployment was observed. The reintervention rate was 33% (Type Ib endoleak, left arm claudication, partial coverage of the left common carotid artery). Clinical success during follow-up was achieved in 10/11 patients. In 9/10 patients, aneurysm sac shrinkage was observed. The Type II endoleak rate was 10% (1/10; intercostal artery). The overall mortality rate was 9% (1 patient died of amyotrophic lateral sclerosis).
CONCLUSIONS: Endovascular treatment of post-coarctation pseudoaneurysms is feasible in elective and emergency cases, yielding durable results in the long term. Due to anatomical specifics, implantation may be challenging and requires careful procedural planning. On-site cardiothoracic surgery backup is essential in case open conversion is required.
© The Author 2015. Published by Oxford University Press on behalf of the European Association for Cardio-Thoracic Surgery. All rights reserved.

Entities:  

Keywords:  Aorta; Aortic coarctation; Pseudoaneurysm; TEVAR; Thoracic endovascular aortic repair

Mesh:

Year:  2015        PMID: 26503013     DOI: 10.1093/icvts/ivv297

Source DB:  PubMed          Journal:  Interact Cardiovasc Thorac Surg        ISSN: 1569-9285


  5 in total

1.  Endovascular repair of the ascending aorta: the last frontier?

Authors:  Drosos Kotelis; Johannes Kalder; Michael J Jacobs
Journal:  J Thorac Dis       Date:  2016-08       Impact factor: 2.895

2.  Result of Thoracic Endovascular Aortic Repair for Patients with Esophageal Cancer.

Authors:  Akira Matsumoto; Yuji Kanaoka; Takeshi Baba; Reo Takizawa; Masayuki Hara; Koji Maeda; Katsunori Nishikawa; Yutaka Suzuki; Katsuhiko Yanaga; Takao Ohki
Journal:  World J Surg       Date:  2018-05       Impact factor: 3.352

3.  Successful Ascending to Descending Aortic Bypass and Endovascular Embolisation of a Late Pseudoaneurysm Following Patch Aortoplasty for Coarctation of the Aorta.

Authors:  Takeshi Kamada; Ryoichi Tanaka; Tomoyuki Iwase; Kotaro Oyama; Hajime Kin
Journal:  EJVES Vasc Forum       Date:  2020-03-17

4.  Impact of extra-anatomical bypass on coarctation fluid dynamics using patient-specific lumped parameter and Lattice Boltzmann modeling.

Authors:  Reza Sadeghi; Benjamin Tomka; Seyedvahid Khodaei; MohammadAli Daeian; Krishna Gandhi; Julio Garcia; Zahra Keshavarz-Motamed
Journal:  Sci Rep       Date:  2022-06-11       Impact factor: 4.996

5.  Successful hybrid TEVAR for distal anastomotic pseudoaneurysm and coarctation following previous palliative left subclavian artery to descending aorta bypass: A case report.

Authors:  Takasumi Goto; Hiroyuki Nishi; Mutsunori Kitahara; Satoshi Sakakibara; Yumi Kakizawa
Journal:  Int J Surg Case Rep       Date:  2020-08-15
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.